PRCT — Procept Biorobotics Corp
NASDAQ · Healthcare · Medical Devices
$20.91
-$0.29 (-1.37%)
Procept Biorobotics Corp (PRCT) is a medical devices company listed on NASDAQ. It is led by Larry L. Wood, based in 150 Baytech Drive, San Jose, CA, United States, 95134, with about 888 employees. PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology in the United States and internationally. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery focusing on treating benign prostatic hyperplasia. The company also provides HYDROS Robotic System, which provides Aquablation therapy image-guided robotic therapy to treat males suffering from lower urinary tract symptoms due to benign prostatic hyperplasia. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.
Latest reported PRCT revenue for 2025-09-30 was $83.3M. Net income was -$21.4M. Revenue was up 5.2% from 2025-06-30 to 2025-09-30. PRCT currently screens at market cap $1.52B.
Use this PRCT page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the PRCT quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the PRCT SEC filings page. Lician reads the product cache first so this HTML stays unique to Procept Biorobotics Corp even when a live quote feed is slow.
About Procept Biorobotics Corp
PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology in the United States and internationally. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery focusing on treating benign prostatic hyperplasia. The company also provides HYDROS Robotic System, which provides Aquablation therapy image-guided robotic therapy to treat males suffering from lower urinary tract symptoms due to benign prostatic hyperplasia. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.
PRCT Key Statistics
Market Cap
$1.52B
Volume
83,360
Previous Close
$21.25
Day Range
$21.04 – $21.48
EPS
-$1.75
Revenue
$224.50M
Net Income
-$91.41M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
+64.8%
Profit Margin
-40.7%
Employees
888
PRCT Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $224.50M | $136.19M | $75.01M | $34.47M |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$91.41M | -$105.90M | -$87.15M | -$59.85M |
| EPS (Diluted) | -$1.75 | -$2.24 | -$1.96 | -$3.63 |
Total Assets
$534.02M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$333.73M
Operating Cash Flow
-$99.21M
Free Cash Flow
$0.00
Procept Biorobotics Corp Company Information
- President, CEO & Director
- Larry L. Wood
- Headquarters
- 150 Baytech Drive, San Jose, CA, United States, 95134
- Website
- www.procept-biorobotics.com
- Phone
- 650 232 7200
- IPO / Founded
- 2021-09-15
- Sector
- Healthcare
- Industry
- Medical Devices